Fujifilm Diosynth Biotechnologies announced a 10-year manufacturing supply agreement, valued at over $3 billion, with Regeneron Pharmaceuticals to provide U.S.-based production of its biologic medicines. Per the terms of the agreement, Fujifilm Diosynth Biotechnologies will provide U.S.-based manufacturing for Regeneron over the next 10 years through current and planned expansions at its new large-scale biopharmaceutical manufacturing facility in Holly Springs, NC, when the sit...